Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients

Journal of the National Cancer Institute

Volumn 107, Issue 10, 2015, Pages

  Yoon, Harry H ^a   Shi, Qian ^a   Alberts, Steven R ^a   Goldberg, Richard M ^b   Thibodeau, Stephen N ^a   Sargent, Daniel J ^a   Sinicrope, Frank A ^a  

^a MAYO CLINIC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; B RAF KINASE; CETUXIMAB; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGE DISTRIBUTION; ARTICLE; ASIAN; BLACK PERSON; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CAUCASIAN; COLON CANCER; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISMATCH REPAIR; MUTATION RATE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; SMOKING; WILD TYPE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER GRADING; CANCER STAGING; COLON TUMOR; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; MORTALITY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL ANALYSIS; UNITED STATES;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COLONIC NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL ANALYSIS; UNITED STATES;

EID: 84944677581     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv186     Document Type: Article

References (55)

1. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1688-1694.
2. Umar A, Greenwald P. Alarming colorectal cancer incidence trends: a case for early detection and prevention. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1672-1673.
3. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
4. Robbins AS, Siegel RL, Jemal A. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 2012;30(4):401-405.
5. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006;24(14):2179-2187.
6. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in africanamerican and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94(15):1160-1167.
7. Yothers G, Sargent DJ, Wolmark N, et al. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011;103(20):1498-1506.
8. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-532.
9. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6(5):322-327.
10. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007; 7(4):295-308.
11. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-867.
12. De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594-603.
13. Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. J Clin Oncol. 2013;31(29):3664-3672.
14. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. Clin Cancer Res. 2012;18(3):890-900.
15. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396-2402.
16. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531-6541.
17. Sylvester BE, Huo D, Khramtsov A, et al. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012;18(2):350-359.
18. Gonsalves WI, Mahoney MR, Sargent DJ, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014;106(7).
19. Brim H, Mokarram P, Naghibalhossaini F, et al. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer. 2008;7:68.
20. Kumar K, Brim H, Giardiello F, et al. Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res. 2009;15(4):1155-1161.
21. Xicola RM, Gagnon M, Clark JR, et al. Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multi-ethnic study. Clin Cancer Res. 2014; 20(18):4962-4970.
22. Brandstedt J, Wangefjord S, Nodin B, et al. Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study. PloS One. 2014;9(2):e98964.
23. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006;98(23):1731-1738.
24. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383-1393.
25. Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. Gastroenterology. 2015;148(1):88-99.
26. Yoon HH, Tougeron D, Shi Q, et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014;20(11):3033-3043.
27. Sinicrope FA, Rego RL, Garrity-Park MM, et al. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer. 2007;120(6):1232-1238.
28. Fairchild AJ, MacKinnon DP. A general model for testing mediation and moderation effects. Prev Sci. 2009;10(2):87-99.
29. Doubeni CA, Major JM, Laiyemo AO, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012;104(18):1353-1362.
30. Breslin TM, Morris AM, Gu N, et al. Hospital factors and racial disparities in mortality after surgery for breast and colon cancer. J Clin Oncol. 2009;27(24):3945-3950.
31. Sinicrope FA, Yoon HH, Mahoney MR, et al. Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. J Clin Oncol. 2014;32(5s):Abstr 3525.
32. Shavers VL. Racial/ethnic variation in the anatomic subsite location of in situ and invasive cancers of the colon. J Natl Med Assoc. 2007;99(7):733-748.
33. Swan J, Breen N, Coates RJ, et al. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97(6):1528-1540.
34. Shavers VL, Jackson MC, Sheppard VB. Racial/ethnic patterns of uptake of colorectal screening, National Health Interview Survey 2000-2008. J Natl Med Assoc. 2010;102(7):621-635.
35. Engen RM, Marsh S, Van Booven DJ, et al. Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets. 2006;7(12):1641-1648.
36. Sanoff HK, Sargent DJ, Green EM, et al. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009;27(25):4109-4115.
37. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138(6):2088-2100.
38. Wallace K, Grau MV, Ahnen D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2310-2317.
39. Qazi TM, O'Brien MJ, Farraye FA, et al. Epidemiology of goblet cell and microvesicular hyperplastic polyps. Amer J Gastroenterol. 2014;109(12):1922-1932.
40. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;102(14):1012-1022.
41. Phatak UR, Kao LS, Millas SG, et al. Interaction between age and race alters predicted survival in colorectal cancer. Ann Surg Oncol. 2013;20(11):3363-3369.
42. Wallace K, Hill EG, Lewin DN, et al. Racial disparities in advanced-stage colorectal cancer survival. Cancer Causes Control. 2013;24(3):463-471.
43. Mayberry RM, Coates RJ, Hill HA, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst. 1995;87(22):1686-1693.
44. Dayal H, Polissar L, Yang CY, et al. Race, socioeconomic status, and other prognostic factors for survival from colo-rectal cancer. J Chronic Dis. 1987;40(9):857-864.
45. Alexander D, Chatla C, Funkhouser E, et al. Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer. 2004;101(1):66-76.
46. Wu X, Chen VW, Martin J, et al. Subsite-specific colorectal cancer incidence rates and stage distributions among Asians and Pacific Islanders in the United States, 1995 to 1999. Cancer Epidemiol Biomarkers Prev. 2004;13(7):1215-1222.
47. American Cancer Society. Colorectal Cancer Facts & Figures 2014-2016. Atlanta: American Cancer Society, 2014.
48. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014;120(15):2316-2324.
49. Popovici V, Budinska E, Tejpar S, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 2012;30(12):1288-1295.
50. Herr R, Kohler M, Andrlova H, et al. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res. 2015;75(1):216-229.
51. Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216-224.
52. Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science. 2001;293(5529):489-493.
53. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348(12):1170-1175.
54. Risch N, Burchard E, Ziv E, et al. Categorization of humans in biomedical research: genes, race and disease. Genome Biol. 2002;3(7):comment2007.
55. Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001;344(18):1392-1393.